Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

PEAL Is Here: Why Front-End Allergen Control Matters More Than Ever

Handmade Food + High-Growth Systems: How Fishbowl scaled up Adelia's Operations

The Arnott's Group appoints its Chief People Officer

The future of food under weight-loss regimes

Tetra Pak launches technology to help make factories AI-ready

Advantech partners with D3 Embedded on AMR sensing and computing

ARC announces $34m in collaborative research funding

Brisbane biomanufacturing hub signs its first tenant

Carbon280 seeks further funding for Hydrilyte technology

Highly precise and safe control of hydrogen testing

InterSystems Launches HealthShare AI Assistant to Optimise Data Retrieval and Clinical Engagement with Conversational Intelligence

Tackle HealthTech AI data challenges early on

Some patients wait 6 years to see a public hospital specialist. Here's how to fix this

19th Victorian Public Healthcare Awards — winners revealed

Remote laundries target preventable disease in NT communities

Lonza bone marrow and cord blood mononuclear cells

Bertin Bioreagent Myelotracker kit for neutrophil detection

Amsbio CELLBANKER cryopreservation solutions

ProImmune ProVE SL Self-Loading MHC Class I Monomers

Content from other channels on our network